Business / Finance

RSS

Dr. Reddy's Laboratories launches public offer to acquire OctoPlus shares

Dr. Reddy's Laboratories Limited, together with its subsidiaries, launches the recommended public offer to acquire all the issued and outstanding shares of OctoPlus N.V., a service-based specialty pharmaceutical company, at an offer price of EUR 0.52 (cum dividend) per share.

14 Dec 2012

Amgen declares $0.47 per share dividend for first quarter 2013

Amgen announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013.

14 Dec 2012

Champions Oncology operating revenues increase to $3.6M for six months ended October 31, 2012

Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended October 31, 2012.

13 Dec 2012

Max Reinhardt named worldwide President of Depuy Synthes Spine

The DePuy Synthes Companies of Johnson & Johnson announced today that Max Reinhardt has been named Worldwide President of DePuy Synthes Spine, a global leader in spinal care. Mr. Reinhardt has been with the company since 2002, most recently as Vice President of Worldwide Marketing.

13 Dec 2012

BioScrip to acquire HomeChoice

BioScrip, Inc. today announced that it has entered into a definitive agreement to acquire HomeChoice Partners, Inc., a leading provider of alternate-site infusion pharmacy services, for $70.0 million in cash.

13 Dec 2012

Concord Medical to acquire 19.98% ownership of MD Anderson Proton Therapy Center

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the signing of a definitive agreement under which it will acquire 19.98% of indirect ownership of The University of Texas MD Anderson Cancer Center Proton Therapy Center (MD Anderson Proton Therapy Center), achieved through acquiring a minority interest in the general partner and facility manager.

13 Dec 2012

Unisense FertiliTech announces new partnership with William Demant Invest

Danish medtech company Unisense FertiliTech A/S announces a new partnership with Oticon Funds investment company William Demant Invest (WDI). WDI owns 32% of Unisense FertiliTech A/S after the purchase of new and existing shares in the company worth 24 million USD.

13 Dec 2012

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts' reported combined revenue from these markets grew 50% in the third quarter of 2012.

13 Dec 2012

First Warning Systems announces Letter of Intent with UniCorp Biotech

First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech.

13 Dec 2012

IRIDEX to purchase 487,500 common stock shares at $4.10 per share

IRIDEX Corporation announced today the preliminary results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m., New York City time, on Friday, December 7, 2012.

10 Dec 2012

Amgen signs definitive agreement to acquire deCODE Genetics

Amgen and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland.

10 Dec 2012

Bay Bridge Capital Partners acquires Plum Healthcare Group

GI Partners ("GI"), a leading mid-market private equity firm, announced today the sale of its portfolio company, Plum Healthcare Group, LLC ("Plum"), one of the fastest growing companies in healthcare services, to Bay Bridge Capital Partners ("Bay Bridge"). The sale of Plum generated a return of approximately three times invested capital for limited partners in GI Partners Fund II L.P.

10 Dec 2012

Verenium signs $22.5 million secured financing with Athyrium

Verenium Corporation, a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a $22.5 million secured debt financing with the Athyrium Opportunities Fund ("Athyrium").

10 Dec 2012

Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C.

10 Dec 2012

Meda signs agreement to acquire MidNite OTC sleep-aid product

Meda has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Annualized revenues for MidNite are approximately 100 MSEK.

7 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

IASIS Healthcare fourth quarter net revenue decreases 2.2% to $633.0 million

IASIS Healthcare LLC, today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2012.

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

Moderna Therapeutics closes $40M in financing

Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development.

6 Dec 2012

Biomatrica completes $5 million in private financing

Biomatrica, Inc., a leader in ambient temperature biostability technology, today announced the completion of $5 million in private financing. Biomatrica has developed SampleMatrix technology which has pioneered recent innovations in ambient storage of biological samples, from purified DNA, RNA, and proteins to complex systems such as tissue, cell lines, biopsies and whole blood.

6 Dec 2012